Gary R Matyas

Dr. Gary R Matyas

Adjuvants and Formulation Section, Laboratory of Adjuvant and Antigen Research, US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2021 in Cell Reports
Verified
Journal Article
Open access
GJGordon Joyce
Gordon Joyce
WCWei-Hung Chen
Wei-Hung Chen
RSRajeshwer S. Sankhala
Rajeshwer S. Sankhala
AHAgnes Hajduczki
Agnes Hajduczki
PTPaul V. Thomas
Paul V. Thomas
KMKayvon Modjarrad
Kayvon Modjarrad
The need for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) next-generation vaccines has been highlighted by the rise of variants of concern (VoCs) and the long-term threat of emerging coronaviruses. Here, we design and characterize four categories of engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of the prefusion SARS-CoV-2 spike (S), S1, and receptor-binding domain (RBD). These immunogens induce robust S binding, ACE2 inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2. A spike-ferritin nanoparticle (SpFN) vaccine elicits neutralizing titers (ID50 > 10,000) following a single immunization, whereas RBD-ferritin nanoparticle (RFN) immunogens elicit similar responses after two immunizations and also show durable and potent neutralization against circulating VoCs. Passive transfer of immunoglobulin G (IgG) purified from SpFN- or RFN-immunized mice protects K18-hACE2 transgenic mice from a lethal SARS-CoV-2 challenge. Furthermore, S-domain nanoparticle immunization elicits ACE2-blocking activity and ID50 neutralizing antibody titers >2,000 against SARS-CoV-1, highlighting the broad response elicited by these immunogens.

16 February 2022 in Science Translational Medicine
Verified
Journal Article
Open access
GJGordon Joyce
Gordon Joyce
HKHannah A. D. King
Hannah A. D. King
IEInes Elakhal-Naouar
Ines Elakhal-Naouar
AAAslaa Ahmed
Aslaa Ahmed
KPKristina K. Peachman
Kristina K. Peachman
KMKayvon Modjarrad
Kayvon Modjarrad
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants stresses the continued need for next-generation vaccines that confer broad protection against coronavirus disease 2019. We developed and evaluated an adjuvanted SARS-CoV-2 spike ferritin nanoparticle (SpFN) vaccine in nonhuman primates. High-dose (50-μg) SpFN vaccine, given twice 28 days apart, induced a T helper cell 1 (T H 1)–biased CD4 T H response and elicited neutralizing antibodies against SARS-CoV-2 wild type and variants of concern, as well as against SARS-CoV-1. These potent humoral and cell-mediated immune responses translated into rapid elimination of replicating virus in the upper and lower airways and lung parenchyma of nonhuman primates after high-dose SARS-CoV-2 respiratory challenge. The immune response elicited by SpFN vaccination and resulting efficacy in nonhuman primates support the utility of SpFN as a vaccine candidate for SARS-causing betacoronaviruses.

1 June 2012 in Expert Review of Vaccines
Verified
Journal Article
Closed access
CACarl R Alving
Carl R Alving
MRMangala Rao
Mangala Rao
NSNicholas J Steers
Nicholas J Steers
GMGary R Matyas
Gary R Matyas
AMAlexander V Mayorov
Alexander V Mayorov
Liposomes containing monophosphoryl lipid A (MPLA) have previously exhibited considerable potency and safety in human trials with a variety of candidate vaccines, including vaccines to malaria, HIV-1 and several different types of cancer. The long history of research and development of MPLA and liposomal MPLA as vaccine adjuvants reveals that there are numerous opportunities for creation and development of generic (nonproprietary) adjuvant system formulations with these materials that are not only highly potent and safe, but also readily available as native materials or as synthetic compounds. They are easily manufactured as potentially inexpensive and easy to use adjuvant systems and might be effective even with synthetic peptides as antigens.

25 February 2016 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
CACarl R. Alving
Carl R. Alving
ZBZoltan Beck
Zoltan Beck
GMGary R Matyas
Gary R Matyas
MRMangala Rao
Mangala Rao
Introduction: Liposomes are well-known as drug carriers, and are now critical components of two of six types of adjuvants present in licensed vaccines. The liposomal vaccine adjuvant field has long been dynamic and innovative, and research in this area is further examined as new commercial products appear in parallel with new vaccines. In an arena where successful products exist the potential for new types of vaccines with liposomal adjuvants, and alternative liposomal adjuvants that could emerge for new types of vaccines, are discussed.Areas covered: Major areas include: virosomes, constructed from phospholipids and proteins from influenza virus particles; liposomes containing natural and synthetic neutral or anionic phospholipids, cholesterol, natural or synthetic monophosphoryl lipid A, and QS21 saponin; non-phospholipid cationic liposomes; and combinations and mixtures of liposomes and immunostimulating ingredients as adjuvants for experimental vaccines.Expert opinion: Liposomes containing mon...

1 June 2013 in Vaccine
Verified
Journal Article
Closed access
GMGary R Matyas
Gary R Matyas
AMAlexander V. Mayorov
Alexander V. Mayorov
KRKenner C. Rice
Kenner C. Rice
AJArthur E. Jacobson
Arthur E. Jacobson
KCKejun Cheng
Kejun Cheng
CACarl R Alving
Carl R Alving

1 January 2007 in Vaccine
Verified
Journal Article
Closed access
SSSathish B. Shivachandra
Sathish B. Shivachandra
QLQin Li
Qin Li
KPKristina K. Peachman
Kristina K. Peachman
GMGary R Matyas
Gary R Matyas
SLStephen H. Leppla
Stephen H. Leppla
VRVenigalla B Rao
Venigalla B Rao